title: Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.
abstract: Thrombolytic efficacy of lonomin V (LV), a protein isolated from Lonomia achelous caterpillars haemolymph, administered either as a single intravenous bolus or as a continuous infusion, was evaluated in a rabbit jugular vein thrombosis model, and compared with those of single-chain tissue-type plasminogen activator (sct-PA) and two-chain urokinase-type plasminogen activator (tcu-PA). As a bolus LV, at doses of 100 000 IU/kg body weight (bw) produced an activator-induced thrombolysis (AIL) of 50.94% +/- 12.4 compared with 14.4% +/- 10.8 for tcu-PA at the same dose. As a continuous infusion at doses of 200 000 IU/kg bw LV produced an AIL of 45.8%, whereas sct-PA and tcu-PA produced an AIL of 69.9 and 33.7%, respectively. Fibrinogen, plasminogen and alpha-2-antiplasmin levels decreased significantly with the higher doses of LV, sct-PA, and tcu-PA. Factor XIII levels were significantly reduced in a dose-dependent manner only with LV. In conclusion, LV produces a dose-dependent thrombolysis in combination with a decrease in factor XIII activity.
authors.affiliation: Instituto Venezolano de Investigaciones Científicas, Carcas, Venezuela. bguerrer@medicina.ivic.ve
authors.forename: B
authors.initials: B
authors.lastname: Guerrero
authors.forename: C L
authors.initials: CL
authors.lastname: Arocha-Piñango
authors.forename: M A
authors.initials: MA
authors.lastname: Pinto
authors.forename: C A
authors.initials: CA
authors.lastname: Müller
authors.forename: A G
authors.initials: AG
authors.lastname: Gil San Juan
authors.forename: S
authors.initials: S
authors.lastname: Amorim
authors.forename: J
authors.initials: J
authors.lastname: Perales
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001180:Arthropod Venoms / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005176:Factor XIII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007601:Jugular Veins; D008297:Male; D010958:Plasminogen / Q000032:analysis; D011817:Rabbits; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000097:blood / Q000188:drug therapy*; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D000925:Anticoagulants; D001180:Arthropod Venoms; D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; C108044:lonomin V; D005340:Fibrinogen; D010958:Plasminogen; D005176:Factor XIII; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator